Skip to main content
SpringerLink
Log in

Caspofungin

A Viewpoint by Ben E. De Pauw

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles [abstract no. 1103]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto: 371

Download references

Author information

Authors and Affiliations

  1. University Medical Center St Radboud, Nijmegen, The Netherlands

    Ben E. De Pauw

Authors
  1. Ben E. De Pauw
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Pauw, B.E. Caspofungin. Drugs 61, 1130 (2001). https://doi.org/10.2165/00003495-200161080-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161080-00008

Search

Navigation